Imugene Limited
IUGNF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.03 | -0.12 | -0.01 |
| FCF Yield | -29.75% | -19.19% | -10.50% | -9.89% |
| EV / EBITDA | -5.40 | -4.93 | -4.59 | -6.84 |
| Quality | ||||
| ROIC | -30.49% | -49.96% | -57.36% | -37.61% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 1.79 | 0.80 | 0.60 | 0.70 |
| Growth | ||||
| Revenue 3-Year CAGR | -6.24% | 7.16% | 26.56% | 53.17% |
| Free Cash Flow Growth | 31.69% | -5.39% | 21.80% | -553.82% |
| Safety | ||||
| Net Debt / EBITDA | 0.60 | 0.37 | 1.18 | 1.92 |
| Interest Coverage | 0.00 | 0.00 | -317.25 | -324.63 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 287.28 | 35.22 | -366.58 | 227.52 |